Valuation: Compugen Ltd.

Market Cap 219M 66.81B 194M 181M 165M 312M 21.07B 315M 2.2B 851M 10.66B 821M 804M 34.53B P/E 2026 *
-8.25x
P/E 2027 * -8.37x
Enterprise Value 219M 66.81B 194M 181M 165M 312M 21.07B 315M 2.2B 851M 10.66B 821M 804M 34.53B EV / Sales 2026 *
23.7x
EV / Sales 2027 * 28.2x
Free-Float
99.84%
Yield 2026 *
-
Yield 2027 * -
1 week+2.22%
1 month-7.62%
3 months+4.17%
6 months+3.99%
Current year+55.75%
1 week 717.5
Extreme 717.5
733.2
1 month 710
Extreme 710
796
Current year 485.2
Extreme 485.2
924
1 year 460.8
Extreme 460.8
924
3 years 208.1
Extreme 208.1
1,175
5 years 208.1
Extreme 208.1
2,358
10 years 208.1
Extreme 208.1
6,766
Manager TitleAgeSince
Chief Executive Officer - 22/09/2025
Director of Finance/CFO 42 14/08/2024
Chief Operating Officer 49 31/12/2023
Director TitleAgeSince
Chairman 59 22/09/2025
Director/Board Member 59 10/06/2018
Director/Board Member 70 10/06/2018
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+2.22% - - 219M
+4.16%+3.04%+49.37%+94.17% 74.16B
-3.11%-3.53%+20.19%+81.44% 57.39B
+0.89%-0.63%+2.17%+36.19% 47.64B
+0.36%+0.81%+342.39%+742.40% 44.29B
-0.96%-4.50%+24.96%+35.38% 42.5B
-0.20%-0.77%+4.13%+105.50% 40.71B
-0.54%+2.93%+9.31%+50.41% 30.97B
-2.68%+2.92%+29.33%+22.72% 28.53B
+0.05%-1.64%-8.14%-11.37% 24.34B
Average -0.20%-0.59%+52.63%+128.54% 43.39B
Weighted average by Cap. +0.12%-0.84%+56.96%+138.26%

Financials

2026 *2027 *
Net sales 9.24M 2.82B 8.21M 7.65M 6.98M 13.17M 890M 13.29M 92.78M 35.93M 450M 34.69M 33.93M 1.46B 7.75M 2.37B 6.89M 6.42M 5.86M 11.04M 746M 11.15M 77.83M 30.14M 378M 29.1M 28.46M 1.22B
Net income -26.46M -8.08B -23.52M -21.91M -19.99M -37.71M -2.55B -38.07M -266M -103M -1.29B -99.35M -97.2M -4.18B -26.95M -8.23B -23.95M -22.32M -20.36M -38.4M -2.6B -38.77M -271M -105M -1.31B -101M -98.99M -4.25B
Net Debt - -
Logo Compugen Ltd.
Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.
Employees
75
Date Price Change Volume
01/10/26 ILA 728.90 0.00% 16,931
30/09/26 ILA 728.90 +0.03% 2,789
29/09/26 ILA 728.70 -0.42% 17,823
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
2.310USD
Average target price
4.600USD
Spread / Average Target
+99.13%

Quarterly revenue - Rate of surprise